Medical Devices

New 24-month clinical data shows Nalu's tiny neurostimulator provides sustained pain relief and improved function, setting a new bar for chronic pain tech.

Acrivon Therapeutics to unveil pivotal data showing high response rates for its targeted drug ACR-368 in an aggressive endometrial cancer subtype.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

A single patient with a debilitating eye pain condition gains access to an investigational therapy, offering hope where no approved treatments exist.

Ozelle will debut an AI system at WHX Labs Dubai that merges three lab functions into one, promising faster, smarter diagnostics for local clinics.

A new in-house lab in Antalya promises international patients faster, more precise dental restorations with unprecedented customization and quality control.

As Embecta prepares its Q1 results, investors watch closely to see if its move beyond insulin can reverse recent revenue declines and reshape its future.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

SPR Therapeutics unveils 12-month data at NANS 2026, showing its temporary SPRINT PNS system provides durable pain relief without a permanent implant.

U.S. firm Catheter Precision secures its first German order for the LockeT device, a strategic move into Europe's largest and most innovative healthcare market.

As Mirion prepares to release its 2025 results, investors are eyeing strong nuclear orders and medical segment growth. What will the numbers reveal?

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

Boutique investment bank Brookline snags four senior pros, signaling a strategic deepening of its expertise in the competitive healthcare and SPAC sectors.

A new, wider diameter range for the GORE VIATORR TIPS Endoprosthesis offers tailored treatment for portal hypertension, promising fewer complications.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

The deal merges BlueRidge's broad life sciences support with Design Science's niche expertise in usability, a critical and mandatory field for FDA approval.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

Trisol Medical's early study reveals its transcatheter valve is safe and effective, offering new hope for high-risk patients with severe heart disease.

A new journal issue reveals how venture capital, advanced clinical insights, and patient-centered drug design are creating a new era in heart failure care.